Cargando…

抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343108/
https://www.ncbi.nlm.nih.gov/pubmed/29551033
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.01.010
_version_ 1783555699678117888
collection PubMed
description
format Online
Article
Text
id pubmed-7343108
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73431082020-07-16 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2018-01 /pmc/articles/PMC7343108/ /pubmed/29551033 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.01.010 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title_full 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title_fullStr 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title_full_unstemmed 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title_short 抗CD19 CAR-T细胞治疗E2A-PBX1阳性复发难治急性B淋巴细胞白血病三例临床分析
title_sort 抗cd19 car-t细胞治疗e2a-pbx1阳性复发难治急性b淋巴细胞白血病三例临床分析
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343108/
https://www.ncbi.nlm.nih.gov/pubmed/29551033
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.01.010
work_keys_str_mv AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī
AT kàngcd19cartxìbāozhìliáoe2apbx1yángxìngfùfānánzhìjíxìngblínbāxìbāobáixuèbìngsānlìlínchuángfēnxī